Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Elias

Showing results (471-480 of 475) with videos related to

Pageof 48
Sort By:
You have reached the last page of results.This site can display upto 475 results.
Nature Medicine|September 14, 2024
Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trialRebecca A Shatsky, Meghna S Trivedi, Christina Yau, et al.
JAMA Oncology|September 16, 2021
Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical TrialW Fraser Symmans, Christina Yau, Yunn-Yi Chen, et al.
JAMA Oncology|July 24, 2020
Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial, Douglas Yee, Angela M DeMichele, et al.
Medrxiv : the Preprint Server for Health Sciences|May 22, 2023
Researching COVID to enhance recovery (RECOVER) pediatric study protocol: Rationale, objectives and designRachel Gross, Tanayott Thaweethai, Erika B Rosenzweig, et al.
Plos One|May 7, 2024
Researching COVID to enhance recovery (RECOVER) pediatric study protocol: Rationale, objectives and designRachel S Gross, Tanayott Thaweethai, Erika B Rosenzweig, et al.
Pageof 48

Showing results (471-480 of 475) with videos related to

Sort By:
Pageof 48
You have reached the last page of results.This site can display upto 475 results.
Nature Medicine|September 14, 2024
Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trialRebecca A Shatsky, Meghna S Trivedi, Christina Yau, et al.
JAMA Oncology|September 16, 2021
Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical TrialW Fraser Symmans, Christina Yau, Yunn-Yi Chen, et al.
JAMA Oncology|July 24, 2020
Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial, Douglas Yee, Angela M DeMichele, et al.
Medrxiv : the Preprint Server for Health Sciences|May 22, 2023
Researching COVID to enhance recovery (RECOVER) pediatric study protocol: Rationale, objectives and designRachel Gross, Tanayott Thaweethai, Erika B Rosenzweig, et al.
Plos One|May 7, 2024
Researching COVID to enhance recovery (RECOVER) pediatric study protocol: Rationale, objectives and designRachel S Gross, Tanayott Thaweethai, Erika B Rosenzweig, et al.
Pageof 48